.

Deeper Knowledge, Faster

  • Predict branded drug patent expiration
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

McKesson
Merck
Harvard Business School
Baxter
Fuji
Argus Health
QuintilesIMS
Teva
Citi
UBS

Generated: June 24, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,258,132

« Back to Dashboard

Which drugs does patent 8,258,132 protect, and when does it expire?


Patent 8,258,132 protects EMEND and is included in two NDAs. There have been four Paragraph IV challenges on Emend.

This patent has forty patent family members in thirty-five countries.

Summary for Patent: 8,258,132

Title:Pharmaceutical composition of a tachykinin receptor antagonist
Abstract: The present invention is directed to novel pharmaceutical compositions of the compound 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluoro)phen- yl-4-(3-(5-oxo-1H,4H-1,2,4-triazolo)methylmorpholine. The pharmaceutical compositions of this invention useful in the treatment or prevention of disorders such as psychiatric disorders including depression and anxiety, inflammatory diseases and emesis.
Inventor(s): Bosch; H. William (Bryn Mawr, PA), Liversidge; Elaine (West Chester, PA), Shelukar; Suhas D. (Lansdale, PA), Thompson; Karen C. (Lansdale, PA)
Assignee: Merck Sharp & Dohme Corp. (Rahway, NJ)
Application Number:10/317,948
Patent Claim Types:
see list of patent claims
Composition; Compound; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Merck
EMEND
aprepitant
CAPSULE;ORAL021549-003Jun 30, 2006ABRXYesNo8,258,132► SubscribeY FOR THE PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH CHEMOTHERAPY
Merck
EMEND
aprepitant
CAPSULE;ORAL021549-003Jun 30, 2006ABRXYesNo8,258,132► SubscribeY PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING
Merck
EMEND
aprepitant
CAPSULE;ORAL021549-001Mar 26, 2003ABRXYesNo8,258,132► SubscribeY PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING
Merck
EMEND
aprepitant
CAPSULE;ORAL021549-001Mar 26, 2003ABRXYesNo8,258,132► SubscribeY FOR THE PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH CHEMOTHERAPY
Merck
EMEND
aprepitant
CAPSULE;ORAL021549-002Mar 26, 2003ABRXYesYes8,258,132► SubscribeY FOR THE PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH CHEMOTHERAPY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,258,132

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada2469315► Subscribe
China1617712► Subscribe
China100352443► Subscribe
Colombia5590887► Subscribe
Germany60227556► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Fuji
US Department of Justice
Chubb
Medtronic
Argus Health
Teva
Federal Trade Commission
Citi
Merck
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot